(OMI) Owens & Minor - Ratings and Ratios
Medical, Surgical, Supplies, Home, Equipment
Dividends
Currently no dividends paid| Risk via 10d forecast | |
|---|---|
| Volatility | 66.7% |
| Value at Risk 5%th | 96.1% |
| Relative Tail Risk | -12.42% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -1.30 |
| Alpha | -91.80 |
| CAGR/Max DD | -0.51 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.729 |
| Beta | 0.860 |
| Beta Downside | 0.687 |
| Drawdowns 3y | |
|---|---|
| Max DD | 91.09% |
| Mean DD | 41.54% |
| Median DD | 42.06% |
Description: OMI Owens & Minor October 23, 2025
Owens & Minor Inc. (NYSE: OMI) is a global healthcare-solutions firm that operates through two primary segments: **Products & Healthcare Services** and **Patient Direct**. The former supplies branded and proprietary medical-surgical items to providers and manufacturers, and adds value with supplier-management, analytics, inventory and clinical-supply services, plus outsourced logistics and marketing programs. The Patient Direct segment focuses on in-home care, delivering diabetes, respiratory-therapy and sleep-apnea products, as well as a broader portfolio that includes ostomy, wound-care, urology and incontinence supplies.
Key financial snapshots (FY 2023) show total revenue of roughly **$7.5 billion**, an operating margin near **5 %**, and free cash flow of about **$200 million**. Recent Q2 2024 results indicated a **3 % year-over-year revenue increase**, driven largely by higher demand for home-care devices and improved supply-chain efficiency that shortened the cash-conversion cycle by roughly **5 days**. The company’s growth is underpinned by macro trends such as an aging U.S. population, the shift toward outpatient and home-based care, and ongoing pressure on hospital margins that heighten demand for cost-saving logistics and inventory-management services.
If you want a data-rich, side-by-side comparison of OMI’s valuation metrics and peer performance, ValueRay’s analyst dashboard offers a convenient, up-to-date view that can help you gauge the stock’s relative attractiveness.
Piotroski VR‑10 (Strict, 0-10) 2.0
| Net Income (-1.34b TTM) > 0 and > 6% of Revenue (6% = 402.4m TTM) |
| FCFTA -0.09 (>2.0%) and ΔFCFTA -8.51pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue -4.98% (prev 3.93%; Δ -8.91pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA -0.02 (>3.0%) and CFO -99.0m > Net Income -1.34b (YES >=105%, WARN >=100%) |
| NO Net Debt/EBITDA fails (EBITDA <= 0) |
| Current Ratio 0.86 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (77.3m) change vs 12m ago 0.26% (target <= -2.0% for YES) |
| Gross Margin 26.13% (prev 32.69%; Δ -6.56pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 147.1% (prev 91.34%; Δ 55.79pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -2.09 (EBITDA TTM -48.8m / Interest Expense TTM 143.0m) >= 6 (WARN >= 3) |
Altman Z'' -2.02
| (A) -0.08 = (Total Current Assets 2.13b - Total Current Liabilities 2.47b) / Total Assets 4.04b |
| (B) -0.25 = Retained Earnings (Balance) -1.02b / Total Assets 4.04b |
| (C) -0.07 = EBIT TTM -298.6m / Avg Total Assets 4.56b |
| (D) -0.20 = Book Value of Equity -898.0m / Total Liabilities 4.47b |
| Total Rating: -2.02 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 16.56
| 1. Piotroski 2.0pt |
| 2. FCF Yield -14.95% |
| 3. FCF Margin -5.25% |
| 4. Debt/Equity -5.11 |
| 5. Debt/Ebitda -44.36 |
| 6. ROIC - WACC (= -20.16)% |
| 7. RoE data missing |
| 8. Rev. Trend -59.47% |
| 9. EPS Trend -30.24% |
What is the price of OMI shares?
Over the past week, the price has changed by +16.22%, over one month by +2.38%, over three months by -43.63% and over the past year by -78.88%.
Is OMI a buy, sell or hold?
- Strong Buy: 2
- Buy: 0
- Hold: 2
- Sell: 2
- Strong Sell: 0
What are the forecasts/targets for the OMI price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 5.7 | 89.4% |
| Analysts Target Price | 5.7 | 89.4% |
| ValueRay Target Price | 1.6 | -47.2% |
OMI Fundamental Data Overview December 11, 2025
P/E Forward = 3.0665
P/S = 0.0179
P/B = 1.0748
P/EG = 4.07
Beta = 1.363
Revenue TTM = 6.71b USD
EBIT TTM = -298.6m USD
EBITDA TTM = -48.8m USD
Long Term Debt = 1.84b USD (from longTermDebt, last quarter)
Short Term Debt = 280.0m USD (from shortTermDebt, last quarter)
Debt = 2.20b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 2.16b USD (from netDebt column, last quarter)
Enterprise Value = 2.36b USD (192.6m + Debt 2.20b - CCE 32.8m)
Interest Coverage Ratio = -2.09 (Ebit TTM -298.6m / Interest Expense TTM 143.0m)
FCF Yield = -14.95% (FCF TTM -352.2m / Enterprise Value 2.36b)
FCF Margin = -5.25% (FCF TTM -352.2m / Revenue TTM 6.71b)
Net Margin = -19.98% (Net Income TTM -1.34b / Revenue TTM 6.71b)
Gross Margin = 26.13% ((Revenue TTM 6.71b - Cost of Revenue TTM 4.95b) / Revenue TTM)
Gross Margin QoQ = 46.21% (prev 47.60%)
Tobins Q-Ratio = 0.58 (Enterprise Value 2.36b / Total Assets 4.04b)
Interest Expense / Debt = 1.32% (Interest Expense 29.0m / Debt 2.20b)
Taxrate = -54.25% (out of range, set to none) (1.97m / -3.63m)
NOPAT = unknown (EBIT/Op.Income or Taxrate missing)
Current Ratio = 0.86 (Total Current Assets 2.13b / Total Current Liabilities 2.47b)
Debt / Equity = -5.11 (negative equity) (Debt 2.20b / totalStockholderEquity, last quarter -429.5m)
Debt / EBITDA = -44.36 (negative EBITDA) (Net Debt 2.16b / EBITDA -48.8m)
Debt / FCF = -6.14 (negative FCF - burning cash) (Net Debt 2.16b / FCF TTM -352.2m)
Total Stockholder Equity = 106.4m (last 4 quarters mean from totalStockholderEquity)
RoA = -33.21% (Net Income -1.34b / Total Assets 4.04b)
RoE = -1260 % (out of range, set to none) (Net Income TTM -1.34b / Total Stockholder Equity 106.4m)
RoCE = -15.38% (EBIT -298.6m / Capital Employed (Equity 106.4m + L.T.Debt 1.84b))
RoIC = -19.42% (negative operating profit) (EBIT -298.6m / (Assets 4.04b - Curr.Liab 2.47b - Cash 32.8m))
WACC = 0.74% (E(192.6m)/V(2.39b) * Re(9.18%) + (debt cost/tax rate unavailable))
Discount Rate = 9.18% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -33.33 | Cagr: -0.31%
Fair Price DCF = unknown (Cash Flow -352.2m)
EPS Correlation: -30.24 | EPS CAGR: -26.91% | SUE: 0.50 | # QB: 0
Revenue Correlation: -59.47 | Revenue CAGR: -28.61% | SUE: -0.01 | # QB: 0
EPS next Quarter (2026-03-31): EPS=0.15 | Chg30d=-0.002 | Revisions Net=-2 | Analysts=2
EPS next Year (2026-12-31): EPS=0.97 | Chg30d=+0.017 | Revisions Net=-4 | Growth EPS=-4.8% | Growth Revenue=-15.8%
Additional Sources for OMI Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle